Regulation of dopamine D3 receptor in the striatal regions and substantia nigra in diffuse Lewy body disease

Neuroscience

Volumn 248, Issue , 2013, Pages 112-126

  Sun, J ^a,b   Cairns, N J ^c   Perlmutter, J S ^a,c   Mach, R H ^a,c   Xu, J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diffuse Lewy body disease; Dopamine receptors; Parkinson disease; Quantitative autoradiography

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DIHYDROTETRABENAZINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; RACLOPRIDE; RADIOLIGAND; TRITIUM; VESICULAR MONOAMINE TRANSPORTER 2; DRD2 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; SLC18A2 PROTEIN, HUMAN; VESICULAR MONOAMINE TRANSPORTER; WC10 COMPOUND;

AGED; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORPUS STRIATUM; DIFFUSE LEWY BODY DISEASE; FEMALE; HALLUCINATION; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; MALE; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PUTAMEN; QUANTITATIVE ANALYSIS; RECEPTOR DENSITY; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; METABOLISM; NEOSTRIATUM; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; NEOSTRIATUM; PIPERAZINES; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SUBSTANTIA NIGRA; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84880164665     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.05.048     Document Type: Article

References (79)

1. 11C]raclopride. Mov Disord 1997, 12:33-38.
2. Antonini A., Vontobel P., Psylla M., Gunther I., Maguire P.R., Missimer J., Leenders K.L. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995, 52:1183-1190.
3. Barone P., Bankiewicz K.S., Corsini G.U., Kopin I.J., Chase T.N. Dopaminergic mechanisms in hemiparkinsonian monkeys. Neurology 1987, 37:1592-1595.
4. Barone P., Tucci I., Parashos S.A., Chase T.N. D-1 dopamine receptor changes after striatal quinolinic acid lesion. Eur J Pharmacol 1987, 138:141-145.
5. Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003, 9:762-767.
6. 11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain 2009, 132:1366-1375.
7. 11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci 2012, 32:1353-1359.
8. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., Schwartz J.C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci U S A 1997, 94:3363-3367.
9. Bordet R., Ridray S., Schwartz J.C., Sokoloff P. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur J Neurosci 2000, 12:2117-2123.
10. Bowery B.J., Razzaque Z., Emms F., Patel S., Freedman S., Bristow L., Kulagowski J., Seabrook G.R. Antagonism of the effects of (+)-PD 128907 on midbrain dopamine neurones in rat brain slices by a selective D2 receptor antagonist L-741,626. Br J Pharmacol 1996, 119:1491-1497.
11. Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006, 112:389-404.
12. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
13. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
14. 11C-raclopride and positron emission tomography. Ann Neurol 1992, 31:184-192.
15. Ceravolo R., Volterrani D., Gambaccini G., Bernardini S., Rossi C., Logi C., Tognoni G., Manca G., Mariani G., Bonuccelli U., Murri L. Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study. J Neural Transm 2004, 111:1065-1073.
16. 3 receptor ligands. Bioorg Med Chem 2005, 13:77-87.
17. 18F]FDOPA. Psychiatry Res 2008, 163:171-182.
18. Diaz J., Pilon C., Le Foll B., Gros C., Triller A., Schwartz J.C., Sokoloff P. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 2000, 20:8677-8684.
19. Duda J.E. Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr Cogn Disord 2004, 17(Suppl. 1):3-14.
20. Duda J.E., Giasson B.I., Mabon M.E., Lee V.M., Trojanowski J.Q. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 2002, 52:205-210.
21. Fremeau R.T., Duncan G.E., Fornaretto M.G., Dearry A., Gingrich J.A., Breese G.R., Caron M.G. Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proc Natl Acad Sci U S A 1991, 88:3772-3776.
22. Gagnon C., Gomez-Mancilla B., Markstein R., Bedard P.J., Di Paolo T. Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors. Prog Neuropsychopharmacol Biol Psychiatry 1995, 19:667-676.
23. Goldman J.G., Goetz C.G., Brandabur M., Sanfilippo M., Stebbins G.T. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord 2008, 23:2248-2250.
24. 11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol 2010, 13:273-287.
25. Graham W.C., Clarke C.E., Boyce S., Sambrook M.A., Crossman A.R., Woodruff G.N. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res 1990, 514:103-110.
26. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001, 411:86-89.
27. Guttman M., Seeman P., Reynolds G.P., Riederer P., Jellinger K., Tourtellotte W.W. Dopamine D2 receptor density remains constant in treated Parkinson's disease. Ann Neurol 1986, 19:487-492.
28. 11C-N-methyl-spiperone. Acta Neurol Scand 1987, 75:87-94.
29. Hanson J.C., Lippa C.F. Lewy body dementia. Int Rev Neurobiol 2009, 84:215-228.
30. 3H]R(+)-7-OH-DPAT binding in the rat caudate-putamen. Neurochem Int 2001, 38:31-42.
31. Hurley M.J., Jolkkonen J., Stubbs C.M., Jenner P., Marsden C.D. Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and l-DOPA treatment. Brain Res 1996, 709:259-264.
32. Hurley M.J., Stubbs C.M., Jenner P., Marsden C.D. D3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci Lett 1996, 214:75-78.
33. Joyce J.N. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. II. Effects of 6-hydroxydopamine or colchicine microinjections into the VTA or reserpine treatment. Exp Neurol 1991, 113:277-290.
34. Joyce J.N., Marshall J.F., Bankiewicz K.S., Kopin I.J., Jacobowitz D.M. Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density. Brain Res 1986, 382:360-364.
35. Joyce J.N., Ryoo H.L., Beach T.B., Caviness J.N., Stacy M., Gurevich E.V., Reiser M., Adler C.H. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors. Brain Res 2002, 955:138-152.
36. Kliem M.A., Maidment N.T., Ackerson L.C., Chen S., Smith Y., Wichmann T. Activation of nigral and pallidal dopamine D1-like receptors modulates basal ganglia outflow in monkeys. J Neurophysiol 2007, 98:1489-1500.
37. Kliem M.A., Pare J.F., Khan Z.U., Wichmann T., Smith Y. Comparative ultrastructural analysis of D1 and D5 dopamine receptor distribution in the substantia nigra and Globus pallidus of monkeys. Adv Behav Biol 2009, 58:239-253.
38. 11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement 2008, 4:S67-S76.
39. Kotzbauer P.T., Cairns N.J., Campbell M.C., Willis A.W., Racette B.A., Tabbal S.D., Perlmutter J.S. Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia. Arch Neurol 2012, 1-6.
40. Kumakura Y., Gjedde A., Danielsen E.H., Christensen S., Cumming P. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms. J Cereb Blood Flow Metab 2006, 26:358-370.
41. LaHoste G.J., Marshall J.F. Chronic eticlopride and dopamine denervation induce equal nonadditive increases in striatal D2 receptor density: autoradiographic evidence against the dual mechanism hypothesis. Neuroscience 1991, 41:473-481.
42. Levesque D., Martres M.P., Diaz J., Griffon N., Lammers C.H., Sokoloff P., Schwartz J.C. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Natl Acad Sci U S A 1995, 92:1719-1723.
43. Lim M.M., Xu J., Holtzman D.M., Mach R.H. Sleep deprivation differentially affects dopamine receptor subtypes in mouse striatum. NeuroReport 2011, 22:489-493.
44. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., Aarsland D., Arai H., Ballard C.G., Boeve B., Burn D.J., Costa D., Del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C.G., Gomez-Tortosa E., Halliday G., Hansen L.A., Hardy J., Iwatsubo T., Kalaria R.N., Kaufer D., Kenny R.A., Korczyn A., Kosaka K., Lee V.M., Lees A., Litvan I., Londos E., Lopez O.L., Minoshima S., Mizuno Y., Molina J.A., Mukaetova-Ladinska E.B., Pasquier F., Perry R.H., Schulz J.B., Trojanowski J.Q., Yamada M. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
45. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., Salmon D.P., Lowe J., Mirra S.S., Byrne E.J., Lennox G., Quinn N.P., Edwardson J.A., Ince P.G., Bergeron C., Burns A., Miller B.L., Lovestone S., Collerton D., Jansen E.N., Ballard C., de Vos R.A., Wilcock G.K., Jellinger K.A., Perry R.H. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996, 47:1113-1124.
46. McKeith I., Mintzer J., Aarsland D., Burn D., Chiu H., Cohen-Mansfield J., Dickson D., Dubois B., Duda J.E., Feldman H., Gauthier S., Halliday G., Lawlor B., Lippa C., Lopez O.L., Carlos Machado J., O'Brien J., Playfer J., Reid W. Dementia with Lewy bodies. Lancet Neurol 2004, 3:19-28.
47. Mengod G., Vilaro M.T., Niznik H.B., Sunahara R.K., Seeman P., O'Dowd B.F., Palacios J.M. Visualization of a dopamine D1 receptor mRNA in human and rat brain. Brain Res Mol Brain Res 1991, 10:185-191.
48. Mercuri N.B., Saiardi A., Bonci A., Picetti R., Calabresi P., Bernardi G., Borrelli E. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. Neuroscience 1997, 79:323-327.
49. Morissette M., Goulet M., Grondin R., Blanchet P., Bedard P.J., Di Paolo T., Levesque D. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur J Neurosci 1998, 10:2565-2573.
50. Nikolaus S., Antke C., Muller H.W. In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia. Behav Brain Res 2009, 204:1-31.
51. 1 receptors in Wistar-Kyoto (WKY) and Wistar rats. Life Sci 2008, 83:74-78.
52. Piercey M.F., Moon M.W., Sethy V.H., Schreur P.J., Smith M.W., Tang A.H., Von Voigtlander P.F. Pharmacology of U-91356A, an agonist for the dopamine D2 receptor subtype. Eur J Pharmacol 1996, 317:29-38.
53. Piggott M.A., Marshall E.F., Thomas N., Lloyd S., Court J.A., Jaros E., Burn D., Johnson M., Perry R.H., McKeith I.G., Ballard C., Perry E.K. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999, 122(Pt 8):1449-1468.
54. 123I]-IBZM SPET study. J Neural Transm Suppl 1995, 45:113-122.
55. Prieto G.A., Perez-Burgos A., Palomero-Rivero M., Galarraga E., Drucker-Colin R., Bargas J. Upregulation of D2-class signaling in dopamine-denervated striatum is in part mediated by D3 receptors acting on Ca V 2.1 channels via PIP2 depletion. J Neurophysiol 2011, 105:2260-2274.
56. 3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience 2000, 98:263-273.
57. 3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mice. Synapse 2009, 63:782-793.
58. 2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 1990, 5:55-59.
59. Ryoo H.L., Pierrotti D., Joyce J.N. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov Disord 1998, 13:788-797.
60. 3H]SCH 23390. Brain Res 1986, 375:291-301.
61. Sawle G.V., Playford E.D., Brooks D.J., Quinn N., Frackowiak R.S. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in DOPA naive parkinsonism. Diagnostic implications of the D2 receptor status. Brain 1993, 116(Pt 4):853-867.
62. 11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 2010, 68:392-399.
63. Shinotoh H. Neurotransmitter systems in the human brain studied by positron emission tomography. Rinsho Shinkeigaku 1996, 36:1313-1315.
64. Shinotoh H., Inoue O., Hirayama K., Aotsuka A., Asahina M., Suhara T., Yamazaki T., Tateno Y. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 1993, 56:467-472.
65. 3) as a target for neuroleptics. Nature 1990, 347:146-151.
66. 3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. J Pharmacol Exp Ther 2000, 295:1223-1231.
67. Sun J., Xu J., Cairns N.J., Perlmutter J.S., Mach R.H. Dopamine D(1), D(2), D(3) receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. PLoS One 2012, 7:e49483.
68. Sweet R.A., Hamilton R.L., Healy M.T., Wisniewski S.R., Henteleff R., Pollock B.G., Lewis D.A., DeKosky S.T. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch Neurol 2001, 58:466-472.
69. Tabet N., Walker Z., Mantle D., Costa D., Orrell M. In vivo dopamine pre-synaptic receptors and antioxidant activities in patients with Alzheimer's disease, dementia with Lewy bodies and in controls. A preliminary report. Dement Geriatr Cogn Disord 2003, 16:46-51.
70. Todd R.D., Carl J., Harmon S., O'Malley K.L., Perlmutter J.S. Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons. J Neurosci 1996, 16:7776-7782.
71. 11C]-(+)-PHNO: dissection of D3 signal and anatomy. NeuroImage 2011, 54:264-277.
72. Vonsattel J.P., Del Amaya M.P., Keller C.E. Twenty-first century brain banking. Processing brains for research: the Columbia University methods. Acta Neuropathol 2008, 115:509-532.
73. Wade T.V., Rothblat D.S., Schneider J.S. Changes in striatal dopamine D3 receptor regulation during expression of and recovery from MPTP-induced parkinsonism. Brain Res 2001, 905:111-119.
74. Walker Z., Costa D.C., Janssen A.G., Walker R.W., Livingstone G., Katona C.L. Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 1997, 24:609-614.
75. Walker Z., Costa D.C., Walker R.W., Shaw K., Gacinovic S., Stevens T., Livingston G., Ince P., McKeith I.G., Katona C.L. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002, 73:134-140.
76. Wang W., Hahn K.H., Bishop J.F., Gao D.Q., Jose P.A., Mouradian M.M. Up-regulation of D3 dopamine receptor mRNA by neuroleptics. Synapse 1996, 23:232-235.
77. 3 receptors. I. In vitro characterization. Synapse 2009, 63:717-728.
78. 2 receptor density ratio in the caudate-putamen. Synapse 2010, 64:449-459.
79. Yung K.K., Bolam J.P., Smith A.D., Hersch S.M., Ciliax B.J., Levey A.I. Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 1995, 65:709-730.